Loading clinical trials...

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment

NCT02471222•Adamas Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once daily at bedtime for the treatment of walking impairment in MS. ADS-5102 is designed to be administered once daily at bed time, ADS-5102 achieves higher plasma amantadine concentrations in the early morning, sustained throughout the afternoon, and lower concentrations in the evening when patients are sleeping. ADS-5102 is designed to deliver its primary treatment effect during the day, and potentially reduce the adverse events of immediate-release amantadine when the patient is asleep.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Signed a current IRB-approved informed consent form;
•Male or female subjects between 18 and 70 years of age, inclusive;
•Confirmed diagnosis of Multiple Sclerosis according to the 2010 Revised McDonald criteria;
•On a stable regimen of medications taken specifically to treat MS for at least 30 days prior to screening, and willing to continue the same doses and regimens for the duration of study participation;
•Stable physical activity level for at least 30 days prior to screening and willing to continue without change for the duration of study participation;
•Maximum EDSS score during screening of 6.5;
•Sufficient ambulatory ability to complete two trials of the Timed 25 Foot Walk (T25FW) at the screening visit;
•A score on each completed screening T25FW test between 8 and 45 seconds, inclusive;
•Any other current and allowed prescription/non-prescription medications and/or nutritional supplements taken regularly must have been at a stable dose and regimen for at least 30 days prior to screening, and subject must be willing to continue the same doses and regimens during study participation;
•If taking an antidepressant, must be on a stable dose for at least 60 days prior to screening.

Exclusion Criteria

•History of seizures within 2 years prior to screening;
•Clinically significant MS relapse with onset less than 30 days prior to screening;
•Presence of vertigo or other vestibular dysfunction that might compromise ability to safely perform the T25FW;
•Received physical therapy within 30 days prior to screening;
•Received systemic steroids within 30 days prior to screening;
•Received dalfampridine, methylphenidate, modafinil, armodafinil, amantadine, and/or any product containing amphetamines, or any treatment specifically for fatigue or to improve walking within 30 days prior to screening;
•Received any botulinum toxin containing product used as antispasmodic agent within 3 months prior to screening;
•History of clinically significant hallucinations due to an MS medication or other/unknown cause, within 2 years prior to screening;
•History of Bipolar Disorder or Psychosis, regardless of treatment;
•Presence of cognitive impairment sufficient, in the opinion of the investigator, to affect the subject's ability to complete study assessments, or which would not be in the subject's best interest to participate in the study;
+9 more criteria

Locations (15)

Phoenix, Arizona, United States

Aurora, Colorado, United States

Sarasota, Florida, United States

Atlanta, Georgia, United States

Northbrook, Illinois, United States

Rochester, Minnesota, United States

Lincoln, Nebraska, United States

Albuquerque, New Mexico, United States

Patchogue, New York, United States

Raleigh, North Carolina, United States

Key Dates

Start Date

May 1, 2015

Primary Completion Date

June 1, 2016

Completion Date

June 1, 2016

Last Updated

August 8, 2017

Enrollment

ACTUAL participants

Conditions

Walking ImpairmentMultiple Sclerosis

Interventions

ADS-5102

DRUG

Placebo

OTHER

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504

Secondary Progressive Multiple Sclerosis (SPMS)

View study

RECRUITINGNA

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634

Multiple SclerosisMultiple Sclerosis-Relapsing-Remitting+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 8, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Intermittent Hypoxia in Persons With Multiple Sclerosis

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis